Abstract Details

Title Immigration, Childhood Sunlight Exposure, and Risk of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Topic Multiple Sclerosis

Presentation(s) P14 - Poster Session 14 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-014

Objective To describe immigration history and childhood sunlight exposure in individuals with NMOSD in Toronto, Canada.

Background

Risk of MS is much lower in immigrants to Canada which is thought to be related to childhood sunlight exposure and vitamin D status. There are few established risk factors for NMOSD, although it may be more common in non-white individuals.

Design/Methods This is a preliminary, cross-sectional analysis of NMOSD participants from two academic centres in Toronto who are part of a national case-control study examining risk factors for NMOSD. Eligible participants met the 2015 International Panel for NMOSD diagnosis (IPND) criteria and included aquaporin-4 antibody (AQP4-IgG) positive and negative cases; MOG antibody positive cases were excluded. Participants completed the validated EnvIMS questionnaire, previously used in an international study of environmental risk factors for MS.

Results

Forty-seven subjects have enrolled to date: 42 (89.4 %) women, 37 (78.7%) AQP4-IgG positive, with mean onset age of 43.2 (SD 14.6) years. Thirty-five (85.4%) reported being born outside of Canada and 6 (14.6%) in Canada; data were missing for 5. Twenty-three (65.7%) of the immigrants arrived after the age of 25 and 28 (80.0%) were AQP4-IgG positive. Most common regions of birth were Africa or the Caribbean (n=14; 40.0%%) and East Asia (n=11; 31.4 %). In the overall cohort, 36 (81.8%) reported spending at least 3 hours on average outside during childhood on weekends and holidays.

Conclusions Immigrants comprise a large share of those with NMOSD in Toronto with most having migrated after age 25, whereas relatively few immigrants develop MS and they are more likely to have arrived before adulthood. Environmental risk factors for NMOSD may differ from those for MS, in particular lack of sunlight exposure and vitamin D. These findings will be investigated further in the larger national Canadian cohort with comparison against controls.

Authors/Disclosures
Dina Dababneh, MD PRESENTER	No disclosure on file
Liesly Lee, MD (Sunnybrook Health Sciences Centre)	Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Aventis. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Dalia Rotstein, MD	Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. The institution of Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen/Horizon . Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion . Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Aventis. Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion . Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amgen. The institution of Dr. Rotstein has received research support from MS Canada. The institution of Dr. Rotstein has received research support from National MS Society. Dr. Rotstein has received research support from Li Ka Shing Knowledge Institute. The institution of Dr. Rotstein has received research support from University of Toronto Division of Neurology. The institution of Dr. Rotstein has received research support from Canada's Drug Agency. The institution of Dr. Rotstein has received research support from Amgen. The institution of Dr. Rotstein has received research support from Alexion. The institution of Dr. Rotstein has received research support from Guthy Jackson Foundation .

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details